{"id":408625,"date":"2021-01-05T09:03:53","date_gmt":"2021-01-05T14:03:53","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408625"},"modified":"2021-01-05T09:03:53","modified_gmt":"2021-01-05T14:03:53","slug":"seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/","title":{"rendered":"Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p \/>\n<p \/>\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">Jan. 5, 2021<\/span> \/PRNewswire\/ &#8212; Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted a stock option to purchase 75,000 shares of common stock to one new employee. The stock option was granted pursuant to the Seelos Therapeutics, Inc. 2019 Inducement Plan and granted as an inducement material to the new employee entering into employment with Seelos in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg\" title=\"(PRNewsfoto\/Seelos Therapeutics, Inc.)\" alt=\"(PRNewsfoto\/Seelos Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The stock option has an exercise price equal to <span class=\"xn-money\">$1.46<\/span>, the closing price per share of Seelos&#8217; common stock, as reported by Nasdaq, on <span class=\"xn-chron\">January 4, 2021<\/span>, the date of grant. The option is a non-qualified stock option and 1\/4th of the shares vest on the one-year anniversary of the new employee&#8217;s commencement of employment and an additional 1\/48th of the shares vest monthly thereafter over the next three years, in each case provided that the new employee remains continuously employed by Seelos through the applicable vesting date, inclusive.<\/p>\n<p>Seelos is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>\n        <b>About Seelos Therapeutics<\/b>\n      <\/p>\n<p>Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company&#8217;s robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. <\/p>\n<p>For more information, please visit our website: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3025770-1&amp;h=2916229718&amp;u=http%3A%2F%2Fseelostherapeutics.com%2F&amp;a=http%3A%2F%2Fseelostherapeutics.com\" rel=\"nofollow noopener noreferrer\">http:\/\/seelostherapeutics.com<\/a>, the content of which is not incorporated herein by reference.<\/p>\n<p>\n        <b>Forward-looking Statements<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the employees and equity plans. Risks and uncertainties include risks associated with the Company&#8217;s employees and equity plans, and additional risks set forth in the Company&#8217;s filings with the Securities and Exchange Commission. These forward-looking statements represent the Company&#8217;s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.\u00a0\u00a0<\/p>\n<p>Contact Information:<br \/><span class=\"xn-person\">Anthony Marciano<\/span><br \/>Head of Corporate Communications<br \/>Seelos Therapeutics, Inc. (Nasdaq: SEEL)<br \/>300 Park Ave., 12th Fl.<br \/><span class=\"xn-location\">New York, NY<\/span> 10022<br \/>(646) 293-2136<br \/><a target=\"_blank\" href=\"mailto:anthony.marciano@seelostx.com\" rel=\"nofollow noopener noreferrer\">anthony.marciano@seelostx.com<\/a><br \/><u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3025770-1&amp;h=3727505645&amp;u=http%3A%2F%2Fwww.seelostherapeutics.com%2F&amp;a=www.seelostherapeutics.com\" rel=\"nofollow noopener noreferrer\">www.seelostherapeutics.com<\/a><\/u><br \/><u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3025770-1&amp;h=2971903600&amp;u=https%3A%2F%2Ftwitter.com%2Fseelostx&amp;a=https%3A%2F%2Ftwitter.com%2Fseelostx\" rel=\"nofollow noopener noreferrer\">https:\/\/twitter.com\/seelostx<\/a><\/u><br \/><u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3025770-1&amp;h=1814722342&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fseelos&amp;a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fseelos\" rel=\"nofollow noopener noreferrer\">https:\/\/www.linkedin.com\/company\/seelos<\/a><\/u><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY37057&amp;sd=2021-01-05\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-301200562.html\">http:\/\/www.prnewswire.com\/news-releases\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-301200562.html<\/a><\/p>\n<p>SOURCE  Seelos Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY37057&amp;Transmission_Id=202101050900PR_NEWS_USPR_____NY37057&amp;DateId=20210105\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK, Jan. 5, 2021 \/PRNewswire\/ &#8212; Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted a stock option to purchase 75,000 shares of common stock to one new employee. The stock option was granted pursuant to the Seelos Therapeutics, Inc. 2019 Inducement Plan and granted as an inducement material to the new employee entering into employment with Seelos in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price equal to $1.46, the closing price per share of Seelos&#8217; common stock, as reported by Nasdaq, on January 4, 2021, the date of grant. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408625","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Jan. 5, 2021 \/PRNewswire\/ &#8212; Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted a stock option to purchase 75,000 shares of common stock to one new employee. The stock option was granted pursuant to the Seelos Therapeutics, Inc. 2019 Inducement Plan and granted as an inducement material to the new employee entering into employment with Seelos in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price equal to $1.46, the closing price per share of Seelos&#8217; common stock, as reported by Nasdaq, on January 4, 2021, the date of grant. The &hellip; Continue reading &quot;Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T14:03:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2021-01-05T14:03:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/\"},\"wordCount\":414,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/\",\"name\":\"Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\",\"datePublished\":\"2021-01-05T14:03:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/","og_locale":"en_US","og_type":"article","og_title":"Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"PR Newswire NEW YORK, Jan. 5, 2021 \/PRNewswire\/ &#8212; Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted a stock option to purchase 75,000 shares of common stock to one new employee. The stock option was granted pursuant to the Seelos Therapeutics, Inc. 2019 Inducement Plan and granted as an inducement material to the new employee entering into employment with Seelos in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price equal to $1.46, the closing price per share of Seelos&#8217; common stock, as reported by Nasdaq, on January 4, 2021, the date of grant. The &hellip; Continue reading \"Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T14:03:53+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2021-01-05T14:03:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/"},"wordCount":414,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/","name":"Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","datePublished":"2021-01-05T14:03:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408625"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408625\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}